TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021

Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.

Alison J Moskowitz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.